retatrutide triple agonist glp-1 gip glucagon receptors ly3437943 mechanism Beyond GLP -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Targeting GLP-1, GIP & GCG
Pay in 4 interest-free payments of $6.29 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
























-1775582746855.png&w=3840&q=75)